Meanwhile, AKT1, MYC, HSP90AA1, HIF1A, ESR1, TP53, and STAT3 are the potential therapeutic targets of LGZGD in treating NAFLD. Here, MYC is linked to metabolic dysfunction-associated steatotic liver disease.